Cytotoxic T-lymphocyte antigen-4 blockade in melanoma
EI Buchbinder, DF McDermott - Clinical therapeutics, 2015 - Elsevier
Purpose Melanoma is an aggressive malignancy that has a complex relationship with the
host immune system. Immunotherapies have long been a mainstay of melanoma therapy,
and advanced therapies continue to be effective in treating this disease. Immune checkpoint
blockade has proven to be a novel target in melanoma, with the approval of cytotoxic T-
lymphocyte antigen-4 (CTLA-4)–targeted therapy. This review evaluates the role of CTLA-4–
targeted therapies in the treatment of metastatic melanoma, with a focus on mechanisms …
host immune system. Immunotherapies have long been a mainstay of melanoma therapy,
and advanced therapies continue to be effective in treating this disease. Immune checkpoint
blockade has proven to be a novel target in melanoma, with the approval of cytotoxic T-
lymphocyte antigen-4 (CTLA-4)–targeted therapy. This review evaluates the role of CTLA-4–
targeted therapies in the treatment of metastatic melanoma, with a focus on mechanisms …